ArticleScientific reports2025
Synthesis and in silico studies of new thiophene-isoquinolinone hybrids as potential larvicides against Culex pipiens.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Synthesis, anti-proliferative evaluation, DFT,RSC advances · 2026Article
- Biological activity of 2-methylbenzimidazole derivatives with heterocyclic rings on development ofJournal of pesticide science · 2026Article
- Design, synthesis, and insecticidal potency of novel 3-methyl-pyrazole derivatives against Culex pipiens larvae.Scientific reports · 2026Article
- New benzochromene-based compounds as potential EGFR-TK inhibitors: synthesis, anti-proliferative activity, molecular docking studies, and ADME profiles.RSC advances · 2026Article
- Integrated synthesis, antiproliferative potential, andRSC advances · 2026Article
- Transformation of 3-(4-methoxybenzylidine)-5-(RSC advances · 2026Article
- Synthesis, SAR, and in silico studies of new benzochromene derivatives as insecticidal agents against Culex pipiens L. larvae and adults.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mosquito-borne diseases remain a significant global public health challenge. This challenge is further exacerbated by the growing resistance of disease-vector species such as Culex pipiens to conventional insecticides. In this study, we present the design, synthesis, and biological assessment of a new series of thiophene-isoquinolinone hybrids as potential larvicides. Among the synthesized compounds, derivatives 5f, 6, and 7 showed significant larvicidal effectiveness against Culex pipiens larvae, with LC₅₀ values of 0.3, 0.1, and 1.85 µg/mL, respectively. Notably, all twelve thiophene-isoquinolinone derivatives were much more toxic than the reference organophosphate insecticide chlorpyrifos (LC₅₀ = 293.8 µg/mL), demonstrating the strength of these chemical structures. Interestingly, the synthetic intermediate compound 1a, a thiophene-based half-ester, exhibited the highest activity (LC₅₀ = 0.004 µg/mL), outperforming all final derivatives despite not being fully optimized. Mechanistic bioassays showed consistent neurotoxic symptoms that suggest a disruption of cholinergic function. Molecular docking and molecular dynamics simulations supported this observation, revealing strong and specific interactions with both acetylcholinesterase (AChE) and nicotinic acetylcholine receptors (nAChRs), which points to a possible dual-target mechanism. Density Functional Theory (DFT) calculations further confirmed the favorable electronic properties and reactivity of the active compounds. The structural variety within this series, along with consistently high potency, may lower the risk of cross-resistance and aid resistance management strategies through compound rotation or combination. Overall, these findings highlight thiophene-isoquinolinone hybrids as a promising option for developing next-generation larvicides that target neurophysiological pathways in insect vectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.